ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Following tetracycline removal, induction of BCR-ABL expression and evidence of CML-like disease, four cohorts of mice were treated with vehicle, Lys05, nilotinib or the combination for three weeks (Fig. 6a).